Navigation Links
Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of Nearly $5 Billion in the First Nine Months of 2007
Date:11/27/2007

Currently, Over 370 Agents are in Active Clinical Development, Addressing

Over 190 Targets

LAKE FOREST, Calif., Nov. 27 /PRNewswire/ -- Six ErbB (EGFr/HEr2)-pathway inhibitors, marketed for the treatment of several major solid tumor indications, generated global sales of $4,964.4 million in the first 9 months of 2007, almost surpassing the $5,160 million total revenues of these agents in 2006.

Despite this unprecedented market success and the acceptance of targeted therapies in oncology practice, many challenges remain unfulfilled. One key problem of currently approved agents is the relatively marginal benefits they provide; median progression-free survival (PFS) and overall survival (OS) are extended only by a few months. However, aggressive efforts to overcome current limitations are providing unique opportunities in this field.

Currently, all targeted therapeutics, both approved and novel are under evaluation almost exclusively in combination with approved cytotoxic agents. Because cytotoxics remain the treatment mainstay for adjuvant, neoadjuvant and advanced/metastatic disease, opportunities still exist for the development of more effective, less toxic alternatives.

Targeted therapeutics are also under investigation in combination with each other, in efforts to simultaneously inhibit additional or compensating pathways, or to maximize effectiveness against a single target by combining drugs acting by different mechanisms, e.g., receptor tyrosine kinase (RTK) inhibitors and monoclonal antibodies (MAb), against the same target. Also, multitargeted inhibitors are in development against different targets in the same or different pathways hypothesized to act in concert in malignancy.

The commercial success of the ErbB inhibitors and other targeted anticancer agents has stimulated R&D in this field. More than 370 drugs have entered clinical trials, with many having already reached phase II (n=183) or phase III (n=43) stages of development. In addition hundreds of agents are in preclinical development. Their mechanisms of action are wide ranging, targeting some of the more than 1,000 different molecular markers implicated in malignancy.

Molecularly targeted agents in development are ushering in the age of personalized medicine. There is pressing need for better diagnostic, theragnostic, prognostic, pharmacogenomic and disease monitoring methodologies for patient selection and optimized treatment.

The source, mechanisms of action, and preclinical and clinical status, including interim and final trial results, of all of these agents are described in detail in New Medicine's Oncology KnowledgeBASE (nm/OK). By interrogating nm/OK users may:

-- Identify novel agents addressing either a single target or multiple

pathways/targets and review in detail their preclinical and clinical

status

-- Locate targeted agents in clinical trials in combination with specific

approved cytotoxic agents or classes of such drugs, i.e. platinum-based

agents, taxanes, etc.

-- Obtain comprehensive, cited data on over 1,000 targets that may be

applicable as diagnostic, theragnostic, prognostic, pharmacogenomic,

disease monitoring and/or therapeutic targets in cancer

-- Obtain interim and final results of combination trials of approved

anticancer agents, by cancer indication, target, clinical development

status, etc.

-- Obtain detailed records of anticancer targets by 100 different cancer

indications, and many subtypes such as non-small cell lung cancer

(nsclc), triple receptor-negative breast cancer, glioblastoma

multiforme (GBM), etc.

-- View detailed records of drugs in development for several hundred

highly specific clinical indications, i.e. advanced or metastatic

disease, adjuvant or neoadjuvant treatment, first line or second line

treatment

-- Obtain detailed preclinical and/or clinical pipelines of over 1,000

developers of anticancer agents, including detailed profiles of the

companies and their affiliates

-- Identify licensing opportunities

-- Assess global market opportunities based on revenues of approved drugs

and the epidemiology of specific cancer indications

-- Create proprietary 'saved searches' to monitor developments in a

pre-selected group of agents chosen by specific shared parameters,

i.e., targets, delivery systems, mechanism of action, cancer

indication, clinical indication, stage of development, etc.

Contact us for an on line demonstration of nm/OK.

Contact: Katie Siafaca

Tel: (949) 830-0448;

Fax: (949) 830-0887

E-mail: info@newmedinc.com

http://www.newmedinc.com

http://nmok.net

http://nmok.net/oksite/samprecords.html


'/>"/>
SOURCE New Medicine's Oncology KnowledgeBASE
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Study suggests brain tumors need treatment with multiple targeted drugs
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: